China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a Phase IIa trial of its KRAS G12C inhibitor, JAB-21822, for first-line non-small cell lung cancer (NSCLC) with KRAS G12C and STK11 co-mutations. The study follows a Phase I trial that showed a 56.3% objective response rate (ORR) and 90.6% disease control rate (DCR) in KRAS G12C mutant NSCLC patients.
Drug Profile
JAB-21822, an in-house developed small-molecule inhibitor, is positioned as a potential best-in-class KRAS G12C therapy. The drug is under investigation in multiple Phase I/II trials in China, the U.S., and Europe, targeting NSCLC, pancreatic ductal carcinoma, and colorectal cancer. It is being tested as a monotherapy and in combination with EGFR antibodies or Jacobio’s SHP2 inhibitor JAB-3312.
Clinical Development
The Phase IIa trial in China will evaluate JAB-21822’s efficacy and safety in first-line NSCLC patients with KRAS G12C/STK11 co-mutations. The drug’s dual-mechanism approach aims to address resistance pathways and improve outcomes in hard-to-treat cancers.
Strategic Outlook
Jacobio plans to expand JAB-21822’s clinical program globally, leveraging its strong Phase I data to pursue approvals in key markets. The company’s pipeline includes multiple KRAS-targeted therapies, positioning it as a leader in addressing unmet needs in oncology.-Fineline Info & Tech
